In vitro bactericidal activity of lactoferricin and other enzymes on bacteria selected from dogs with pyoderma

Global Veterinary Microbiology and Veterinary Medicine Summit

October 17-18, 2016 Chicago, USA

Natascia Bruni and A Vercelli

Istituto Farmaceutico Candioli, Italy
Ambulatorio Veterinario Associato, Italy

Scientific Tracks Abstracts: J Veterinar Sci Techno

Abstract :

Lactoferricin (LFcin) is a peptide with antimicrobial activity against microorganisms such as Gram negative and positive bacteria, including some antibiotic-resistant pathogens. Others enzymes like dextrozyme, alcalase and amylase may be associated to the LFcin to enhance its antimicrobial action. The aim of this study was to evaluate the in vitro activity of LFcin associations with dextrozyme (LFD), alkalase (LFL) and amylase (LFM) against Staphylococcus pseudintermedius, Escherichia coli, Proteus vulgaris and Pseudomonas aeruginosa strains isolated from dogs with pyoderma. The evaluation was performed using minimum inhibitory concentrations with a microtiter plate dilution method starting by an LFcin/enzymes solution at 11%. The bacterial inoculums in log-phase growth were prepared in brain heart infusion broth (BHI) with a turbidity of 0.5 McFarland, corresponding to 102 to 103 cells/ml. Dilutions in BHI at 2:1 (7.5%), 1:1 (5.5%), 1:2 (3.7%) and 1:5 (1.8%) were used for each bacteria. Negative and positive controls were included. All the wells were incubated 10 �¼l on blood agar at 37 �°C for 48 hours to confirm the bacterial inhibition. The associations LFD and LFM showed bactericidal activity against all the isolates at 7.3%, at 5.5%, only for S. pseudintermedius at 3.7%. The LFL showed inhibition at 3.7% for all strains and resistance at 1.8%. These results suggest that the associations of LFcin with other enzymes improve its antimicrobial activity. The LFL exhibits in vitro bactericidal activity even against a strain of multidrug resistant P. aeruginosa at low concentrations. LFcin and its associations should be a new topical treatment of skin infections.

Biography :

Natascia Bruni has completed her PhD from University of Turin and Postdoctoral studies from High Synthesis School of Gargnano, Italy. She is the Director of Research and Development in Candioli Pharma. She has published more than 10 papers in reputed journals.

Email: natascia.bruni@candioli.it